BIO.B PE Ratio & Valuation, Is BIO.B Overvalued

Historical Valuation

Bio Rad Laboratories Inc (BIO.B) is now in the Fair zone, suggesting that its current forward PE ratio of 29.16 is considered Fairly compared with the five-year average of 28.96. The fair price of Bio Rad Laboratories Inc (BIO.B) is between 240.70 to 271.59 according to relative valuation method.

Relative Value

Fair Zone

240.70-271.59

Current Price：268.55

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Bio Rad Laboratories Inc (BIO.B) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Bio Rad Laboratories Inc (BIO.B) has a current Price-to-Book (P/B) ratio of 1.22. Compared to its 3-year average P/B ratio of 1.20, the current P/B ratio is approximately 1.59% higher. Relative to its 5-year average P/B ratio of 1.20, the current P/B ratio is about 1.59% higher. Bio Rad Laboratories Inc (BIO.B) has a Forward Free Cash Flow (FCF) yield of approximately 4.08%. Compared to its 3-year average FCF yield of 3.58%, the current FCF yield is approximately 13.92% lower. Relative to its 5-year average FCF yield of 3.58%, the current FCF yield is about 13.92% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BIO.B competitors is 101.26, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO.B.N) exhibits a P/S ratio of 3.14, which is -96.9% above the industry average. Given its robust revenue growth of 3.85%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BIO.B increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BIO.B in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BIO.B currently overvalued or undervalued?

What is Bio Rad Laboratories Inc (BIO.B) fair value?

BIO.B's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Bio Rad Laboratories Inc (BIO.B) is between 240.70 to 271.59 according to relative valuation method.

How does BIO.B's valuation metrics compare to the industry average?

The average P/S ratio for BIO.B's competitors is 101.26, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO.B) exhibits a P/S ratio of 3.14, which is -96.90% above the industry average. Given its robust revenue growth of 3.85%, this premium appears unsustainable.

What is the current P/B ratio for Bio Rad Laboratories Inc (BIO.B) as of Mar 17 2026?

As of Mar 17 2026, Bio Rad Laboratories Inc (BIO.B) has a P/B ratio of 1.22. This indicates that the market values BIO.B at 1.22 times its book value.

What is the current FCF Yield for Bio Rad Laboratories Inc (BIO.B) as of Mar 17 2026?

As of Mar 17 2026, Bio Rad Laboratories Inc (BIO.B) has a FCF Yield of 4.08%. This means that for every dollar of Bio Rad Laboratories Inc's market capitalization, the company generates 4.08 cents in free cash flow.

What is the current Forward P/E ratio for Bio Rad Laboratories Inc (BIO.B) as of Mar 17 2026?

As of Mar 17 2026, Bio Rad Laboratories Inc (BIO.B) has a Forward P/E ratio of 29.16. This means the market is willing to pay $29.16 for every dollar of Bio Rad Laboratories Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bio Rad Laboratories Inc (BIO.B) as of Mar 17 2026?

As of Mar 17 2026, Bio Rad Laboratories Inc (BIO.B) has a Forward P/S ratio of 3.14. This means the market is valuing BIO.B at $3.14 for every dollar of expected revenue over the next 12 months.

BIO.B Valuation